SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation....
Hence then, the article about ind application for nts071 nutshell therapeutics p53 y220c allosteric reactivator received us fda clearance was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance )
Also on site :
- San Antonio Spurs Canceling Knicks Fans’ Tickets for NBA Finals Game 5
- Country Star Makes Billboard Chart History With No. 1 Hit Song Lasting 28 Weeks
- Innoscience Secures Final Victory in Patent Lawsuit as China's Supreme Court Upholds Injunction Against Infineon GaN Products